Brief Definitive Report

Conversion of a Self Peptide Sequence into a K^d-restricted Neo-Antigen by a Tyr Substitution

By Frank Healy, Christian Drouet,* Pedro Romero, Christian Jaulin,‡ and Janet L. Maryanski

*From the Ludwig Institute for Cancer Research, Lausanne Branch, 1066 Epalinges, Switzerland; *INSERM U238, 38041 Grenoble Cedex; and the ‡Institut Pasteur, 75724 Paris Cedex 15, France*

Summary

We have previously found that a Tyr residue was critical for the interaction of peptides with the K^d molecule, and therefore may be acting as an anchor residue. In the present report we show that it is possible to convert a self peptide sequence into a K^d-restricted neo-antigen by a single Tyr substitution at position 2 of the peptide. This supports the idea that Tyr is a critical element in the binding motif of K^d-restricted peptides and is a finding that could also prove useful for vaccine development.

Downloaded from http://rupress.org/jem/article-pdf/174/6/1657/1102118/1657.pdf by guest on 04 December 2022

T lymphocytes recognize antigen in the form of peptides bound to MHC class I or class II molecules (reviewed in references 1 and 2). x-ray crystallographic analysis of the class I molecules HLA-A2 and HLA-Aw68 (3–5) showed a cleft on the MHC molecule that was proposed to be the peptide binding site. By using a functional competition assay we have recently tried to define common structural features of peptides recognized in the context of the H-$2K^d$ (K^d) MHC class I molecule (6). For the antigenic peptide HLA-A24 170-182, it was initially shown that three residues (Tyr 171, Thr 178, and Leu 179) were important in the interaction with K^d. Subsequently, an analogue (AYP_5TLA) containing these residues was demonstrated to be an efficient competitor for K^d binding. A predominant influence on binding was found for the Tyr residue and we have demonstrated that four different K^d-restricted peptides all contain a common Tyr residue that appears to be critical for competitor activity (6, 7).

We reasoned that if Tyr was a critical residue for K^d binding, it should be possible to introduce a Tyr residue into a protein sequence and create a neo-epitope restricted by K^d. To test this, we took advantage of the well characterized antigenic mutant system developed by Boon et al. (reviewed in reference 8). They have shown that a high frequency of mutagenized P815 tumor cells express neo-antigens that can be recognized by CTL. The mutants are rejected by syngeneic mice, and hence they have been named tum$^-$ ("tumor-minus") mutants. For three different tum$^-$ mutants, the genes encoding the neo-antigens have been cloned and sequenced. The three genes, which are unrelated to each other and whose functions are as yet unknown, each contain a single point mutant that leads to the creation of a neo-epitope (8). One example is tum$^-$ antigen P91A$^-$, in which the point mutation resulted in a single amino acid change that created an L^d-restricted CTL epitope (9).

To initiate the present study, we synthesized a series of six overlapping 11-mer peptides whose sequences correspond to the wild-type (i.e., self) P91A$^+$ (tum$^+$) sequence, except for the replacement of a single residue in each peptide with Tyr. The Tyr residue was introduced at the second position from the NH_2 terminus in each peptide, since this position was found to be optimal for the four different K^d-restricted epitopes that we have analyzed previously (10). After testing these six peptides in a competition assay, we selected one that appeared to be optimal for K^d binding and immunized mice of the H-2^d MHC haplotype. From these mice we could isolate CTL specific for the immunizing peptide, and as predicted, all of the CTL clones thus obtained were H-$2K^d$ restricted.

Materials and Methods

Cells. The isolation and characterization of K^d-restricted CTL clone CS.H2 (P. Romero et al., manuscript in preparation) and of L^d-restricted CTL clone P91.6 (11) is described elsewhere. The CTL lines and clones specific for the peptide P91A 12-22/Y_{13} were isolated from BALB/c or (BALB/c × C57BL/6)F_1 mice immunized with the peptide in Freund's adjuvant, as described elsewhere (P. Romero et al., manuscript in preparation).

Peptides. Peptides were synthesized and purified as described elsewhere (6), and amino acid composition was confirmed by amino acid analysis.

Cytolytic Assay. Experiments to assess peptide recognition or competition were performed as described elsewhere (6) in a 4-h ^{51}Cr release assay. The percent specific lysis was calculated as: 100× [(experimental − spontaneous release)/(total − spontaneous

 J. Exp. Med. © The Rockefeller University Press • 0022-1007/91/12/1657/04 $2.00
Volume 174 December 1991 1657–1660

Table 1. *Peptides Used in this Study*

Peptide	Sequence
P91A⁺.12-24	I S T Q N R R A L D L V A
P91A⁻.12-24	I S T Q N H R A L D L V A
11-21/Y_{12}	K Y S T Q N R R A L D
12-22/Y_{13}	I Y T Q N R R A L D L
13-23/Y_{14}	S Y Q N R R A L D L V
14-24/Y_{15}	T Y N R R A L D L V A
15-25/Y_{16}	Q Y R R A L D L V A A
16-26/Y_{17}	N Y R A L D L V A A K

release)]. The percent control lysis was calculated as: 100× [(percent specific lysis with competitor − background lysis)/(percent specific lysis without competitor − background lysis)]. Clone 444/A1.1 (12) was used for P815 (H-2^d) target cells. The derivation of L cell (H-2^k) transfectants that express H-2K^d and/or the mouse inter-cellular adhesion molecule 1 (ICAM-1) is described elsewhere (C. Jaulin et al., manuscript in preparation).

Results and Discussion

The Interaction of Tyr-substituted P91A⁺ Peptides with H-2K^d and H-2L^d. The peptides shown in Table 1 were tested for their capacity to interact with K^d and L^d molecules by using a functional competition assay. The most active competitor for K^d binding was the peptide 12-22/Y_{13}, which was as active as the peptide analogue AYP$_5$TLA previously described (6) (Fig. 1). Peptides Y_{12}, Y_{14}, Y_{15}, and Y_{16} also completed but were 10–100-fold less active, whereas Y_{17} was a poor



Figure 1. Comparison of Tyr-substituted P91A⁺ peptides as competitors for K^d- or L^d-restricted peptides. ^{51}Cr-labeled P815 target cells were incubated with the indicated concentrations (final) of peptides P91A⁺.12-24 (●—●), AYP$_5$TLA (□—□), or MCMV pp89 168-176 (■—■), or with the Tyr-substituted P91A⁺ peptides (see Table 1) Y_{12} (▲—▲), Y_{13} (▲---▲), Y_{14} (△—△), Y_{15} (△---△), Y_{16} (▼—▼), or Y_{17} (▽---▽) as competitors. Antigenic peptides PbCS 252-260 and P91A⁻.12-24 were added at final concentrations of 10^{-10} and 10^{-8} M, respectively, and cells from the K^d-restricted CTL clone CTL-CS.H2 or the L^d-restricted CTL clone CTL-P91.6, respectively, were added at a 3:1 CTL to target ratio in a 4-h ^{51}Cr release assay. Lysis in the absence of competitor peptides was 67% and 63% for CTL-CS.H2 and CTL-P91.6, respectively, and lysis in the absence of peptides was <7%. The competitor peptides were not recognized by either of the test CTL clones (not shown).



Figure 2. CTL specific for the P91A Y_{13} mutant peptide. ^{51}Cr-labeled P815 target cells were added to microtiter plate wells at the indicated (final) concentrations of peptide. Effector cells were added at a 1:1 E/T cell ratio, and the assay was terminated after a 4-h incubation. (*A*) CTL line F_1-1 effector cells were tested with the P91A Y_{13} mutant peptide (●), the P91A⁺ peptide (12-24, ■), or the P91A⁻ peptide (12-24, □). The F_1-1 CTL line was derived from the spleen of a (BALB/c × C57Bl/6)F_1 mouse immunized Sc with the Y_{13} peptide in IFA. The line was restimulated weekly with irradiated BALB/c spleen cells and P815 cells pre-pulsed with the Y_{13} peptide. (*B*) CTL clones 1.1 (●), 1.5 (▲), and 1.6 (▼) were assayed on P815 targets incubated with the P91A Y_{13} peptide (*closed symbols*), the P91A⁺ peptide (*open symbols, solid line*), or the P91A⁻ peptide (*open symbols, broken line*). The CTL clones were isolated from line F_1-1 by limiting dilution after the fourth in vitro stimulation. They express V$_\beta$13, V$_\beta$14, or V$_\beta$10, respectively, and are thus clearly different clones. TCR expression was determined by flow cytometric analysis (not shown) using mAbs specific for V$_\beta$13 (VB-TCR-6B; PharMingen, San Diego, CA) or V$_\beta$14 (14.2; reference 15) and/or by PCR (J.-L. Casanova, personal communication). (*C*) Control CTL clone P91.6 (11) was assayed with the P91A Y_{13} peptide (●), the P91A⁺ peptide (■), and the P91A⁻ peptide (□).

Downloaded from http://rupress.org/jem/article-pdf/174/6/1657/1102118/1657.pdf by guest on 04 December 2022

competitor. The series of Tyr-substituted P91A$^+$ peptides were also tested as competitors for L^d binding. Most of the peptides were relatively inefficient competitors in the L^d system compared with the L^d-restricted reference peptide MCMV pp89 168-176 (13) (Fig. 1). Moreover, the best competitor in the L^d system, peptide Y_{17}, was the least effective competitor in the K^d system, and inversely, peptide Y_{13}, which was the most efficient in the K^d system, did not compete at all in the L^d system.

(BALB/c × C57Bl/6)F_1 and BALB/c Mice Give a K^d-restricted CTL Response when Immunized with Peptide P91A$^+$ Y_{13}. Since the Y_{13} peptide was the optimal K^d binder and the weakest L^d binder, it was selected as an immunogen. A CTL line (F_1-1) obtained from the spleen of a (BALB/c × C57Bl/6)F_1 mouse immunized with the Y_{13} peptide was highly active and specific for the immunizing peptide (Fig. 2 *A*). 11 CTL clones were isolated from the F_1-1 line by limiting dilution and all were found to be specific for the Y_{13} peptide. As shown in Fig. 2 *B*, three of the CTL clones that express different TCR $V\beta$ chains (and can thus be considered different clones) recognize the Y_{13} peptide but not peptides corresponding to the P91A$^+$ (self) sequence, or the P91A$^-$ (tum$^-$) sequence. The latter peptide is recognized by the L^d-restricted CTL clone P91.6 (reference 9 and Fig. 2 *C*). As expected, this control CTL clone did not recognize peptide Y_{13} (Fig. 2 *C*).

All of the CTL clones were shown to be K^d restricted. The results obtained with two independent clones are shown in Fig. 3. The K^d-ICAM-1 double-transfectant target cells were specifically lysed in the presence of the Y_{13} peptide, whereas control K^d-negative transfectant target cells were not. We had found previously that the expression of ICAM-1 on L cells improved levels of lysis (C. Jaulin and J. Maryanski, data not shown).

We have extended these findings by showing that Y_{13}-specific K^d-restricted CTL could be obtained from the spleens of three additional (BALB/c × C57Bl/6)F_1 mice, as well as from two BALB/c mice (Fig. 4).

We have recently defined a simple K^d binding motif for synthetic peptides corresponding to four different K^d-restricted antigens (10). The motif is characterized by a Tyr residue in the second position from the NH_2 terminus, and a hydrophobic residue of Leu, Ile, or Val at position 9 or 10. The optimal peptide from this study (Y_{13}) contains a Leu residue at position 9 and thus incorporates the complete K^d motif that includes the Tyr residue introduced at position 2 (Table 1).

Using chromatographic techniques, Falk et al. (14) have recently identified putative binding motifs in peptides isolated from several different MHC class I molecules. Consistent with our results defining a K^d binding motif, they have shown that naturally occurring peptides bound to K^d appear to be predominantly 9-mers that have a Tyr at position 2 and a COOH-terminal Leu or Ile residue. Our present study provides further confirmation of the validity of the K^d binding



Figure 3. CTL clones specific for the P91A Y_{13} peptide are K^d restricted. ^{51}Cr-labeled L-K^d-ICAM-1 (▲, ▼) or L-ICAM-1 (△, ▽) target cells were added to wells of microtiter plates containing the indicated concentrations (final) of peptide Y_{13}. CTL from clone 1.5 (▲, △) and 1.6 (▼, ▽) were added at a 3:1 CTL to target ratio in a 4-h ^{51}Cr-release assay.



Figure 4. Both BALB/c and (C57Bl/6 × BALB/c)F_1 mouse strains generate K^d-restricted CTL specific for the P91A Y_{13} mutant peptide. ^{51}Cr-labeled L-K^d-ICAM-1 target cells at 2×10^4/ml, were incubated for 15 min with 1 μM of peptide Y_{13}. Cells from CTL lines derived from peptide-immunized mice of either (BALB/c (B-1 [●---●] and B-2 [■---■]) or BALB/c × C57Bl/6)F_1 (F_1-4 [●—●], F_1-5 [▲—▲], and F_1-7 [▼—▼]) strains were added at the indicated lymphocyte to target ratios in a 4-h ^{51}Cr release assay. The results shown were obtained 4 d after the third in vitro restimulation. Lysis in the absence of peptide is indicated by the open symbols. Only marginal lysis was observed on L-ICAM-1 targets in the presence of peptide Y_{13} (not shown).

Downloaded from http://rupress.org/jem/article-pdf/174/6/1657/1102118/1657.pdf by guest on 04 December 2022

motif and also suggests that it may be feasible to predict antigenic epitopes using structural motifs, a finding that could prove useful for vaccine development. Finally, the possibility of designing MHC-directed neo-antigens from self sequences (like P91A$^+$) may be helpful for studies on self tolerance and the TCR repertoire.

We thank K. Mühlethaler and J. Guillou for excellent technical assistance, C. Knabenhans for FACS® analysis, Drs. L. Luescher and G. Corradin for advice on peptide synthesis, Dr. J. Gagnon for peptide sequencing and for advice on amino acid analysis, and A. Zoppi for her secretarial expertise.

Address correspondence to Janet Maryanski, Ludwig Institute for Cancer Research, Ch. des Boveresses 155, 1066 Epalinges, Switzerland.

Received for publication 16 August 1991.

Note Added in Proof: As would be predicted from our recent analysis of other K^d-restricted antigenic peptides (10), we have now found that CTL clones that recognize the 11-mer Y_{13} peptide also recognize the truncated nonamer sequence IYTQNRRAL, which contains the Leu anchor of the K^d binding motif at the COOH-terminus.

Downloaded from http://rupress.org/jem/article-pdf/174/6/1657/1102118/1657.pdf by guest on 04 December 2022

References

1. Milich, D.R. 1989. Synthetic T and B cell recognition sites: Implications for vaccine development. *Adv. Immunol.* 45:195.
2. Townsend, A., and H.C. Bodmer. 1989. Antigen recognition by class I-restricted T lymphocytes. *Annu. Rev. Immunol.* 7:601.
3. Bjorkman, P.J., M.A. Saper, B. Samraoui, W.S. Bennett, J.L. Strominger, and D.C. Wiley. 1987. Structure of the human class I histocompatibility antigen, HLA-A2. *Nature (Lond.).* 329:506.
4. Bjorkman, P.J., M.A. Saper, B. Samraoui, W.S. Bennett, J.L. Strominger, and D.C. Wiley. 1987. The foreign antigen binding site and T-cell recognition regions of class I histocompatibility antigens. *Nature (Lond.).* 329:512.
5. Garrett, T.P.J., M.A. Saper, P.J. Bjorkman, J.L. Strominger, and D.C. Wiley. 1989. Specificity pockets for the side chains of peptide antigens in HLA-Aw68. *Nature (Lond.).* 342:692.
6. Maryanski, J.L., A.S. Verdini, P.C. Weber, F.R. Salemme, and G. Corradin. 1990. Competitor analogs for defined T-cell antigens: peptides incorporating a putative binding motif and polyproline or polyglycine spacers. *Cell.* 60:63.
7. Maryanski, J.L., P. Romero, A. Van Pel, T. Boon, F.R. Salemme, J.-C. Cerottini, and G. Corradin. 1991. The identification of tyrosine as a common key residue in unrelated H-2K^d restricted antigenic peptides. *Int. Immunol.* 3:1035.
8. Boon, T., A. Van Pel, E. De Plaen, P. Chomez, C. Lurquin, J.-P. Szikora, C. Sibille, B. Mariamé, B. Van den Eynde, B. Lethé, and V. Brichart. 1989. Genes coding for T-cell defined tum$^-$ transplantation antigens: point mutations, antigenic peptides, and subgenic expression. *Cold Spring Harbor Symp. Quant. Biol.* 54:587.
9. Lurquin, C., A. Van Pel, B. Mariamé, E. De Plaen, Jr. P. Szikora, C. Janssens, M.J. Reddehase, J. Lejeune, and T. Boon. 1989. Structure of the gene of Tum$^-$ transplantation antigen P91A: the mutated exon encodes a peptide recognized with L^d by cytolytic T cells. *Cell.* 58:293.
10. Romero, P., G. Corradin, I.F. Luescher, and J.L. Maryanski. 1991. H-2K^d restricted antigenic peptides share a simple binding motif. *J. Exp. Med.* 174:603.
11. Maryanski, J.L., J. Van Snick, J.-C. Cerottini, and T. Boon. 1982. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. *Eur. J. Immunol.* 12:401.
12. Maryanski, J.L., R.S. Accolla, and B. Jordan. 1986. H2-restricted recognition of cloned HLA class I gene products expressed in mouse cells. *J. Immunol.* 136:4340.
13. Reddehase, M.J., J.B. Rothbard, and U.H. Koszinowski. 1989. A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes. *Nature (Lond.).* 337:651.
14. Falk, K., O. Rötzschke, S. Stevanovic, G. Jung, and H.-G. Rammensee. 1991. Allele-specific motifs revealed by sequencing of self peptides eluted from MHC molecules. *Nature (Lond.).* 351:290.
15. Liao, N.-S., J. Maltzman, and D.H. Raulet. 1989. Positive selection determines T cell receptor Vβ14 gene usage by CD8$^+$ T cells. *J. Exp. Med.* 170:135.